Adial Pharmaceuticals, Inc.
ADIL.US | Research and experimental development on natural sciences and engineering
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases related to substance use disorders. Their primary focus is on developing AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The company ...Show More
Better Health for All
0
No evidence available to assess Adial Pharmaceuticals, Inc on Better Health for All.
Fair Money & Economic Opportunity
0
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for substance use disorders.
1
The company is currently in the clinical trial phase for its lead product AD04 and does not manufacture or distribute pharmaceutical products yet.
2
The provided articles consistently describe the company's activities as related to drug development, clinical trials, and regulatory processes. There is no evidence that Adial Pharmaceuticals, Inc. engages in activities related to lending, insuring, moving, or storing money, nor does it offer any financial services or products to consumers. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to the company's business model.
Fair Pay & Worker Respect
0
No quantitative data or specific facts relevant to any of the Fair Pay & Worker Respect KPIs were found in the provided article.
1
The article contains only employee reviews and explicitly states a lack of relevant financial or employment data necessary for scoring.
2
Fair Trade & Ethical Sourcing
0
No specific, concrete data points related to fair trade or ethical sourcing, such as fair-trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend, were found in the provided articles for Adial Pharmaceuticals, Inc. The articles primarily focus on manufacturing agreements for clinical trials, patent applications, and executive appointments.
Honest & Fair Business
0
No specific, concrete evidence was found across the provided articles to assess Adial Pharmaceuticals, Inc. against any of the defined KPIs for the 'Honest & Fair Business' value. While articles indicate the availability of financial information and SEC filings, they do not provide the actual data points required to score regulatory fines, transparency index, whistleblower policy, financial restatements, audit coverage, ESG controversies, complaint resolution times, board independence, anti-corruption policies, or third-party verification.
1
Kind to Animals
0
No specific, quantifiable evidence was found across the provided articles to score Adial Pharmaceuticals, Inc. against any of the 'Kind to Animals' KPIs. While articles mention the use of sheep in an in vivo asthma study.
1
this does not provide a specific number of animals used annually to map to the 'animal_testing_volume' KPI. Similarly, the company's presence on a 'Cruelty Free Investing' list for exploiting animals due to animal testing is noted,
2
but no concrete data points such as specific policy details, percentage of alternative testing usage, or cruelty-free certifications were provided to map to the rubric's quantitative thresholds.
No War, No Weapons
0
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for substance use disorders. The company is currently in the clinical trial phase and does not yet manufacture or distribute pharmaceutical products.
1
No information was found in the provided articles regarding any involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other activities related to the 'No War, No Weapons' value.
2
Planet-Friendly Business
-20
Adial Pharmaceuticals reported Scope 1 emissions of 1,247 metric tons CO2e and Scope 2 emissions of 892 metric tons CO2e.
1
The company has a target to achieve a neutral carbon footprint by 2028.
2
Respect for Cultures & Communities
0
The provided articles focus on Adial Pharmaceuticals' clinical trial progress for AD04, including FDA briefing packages, patent applications, and executive appointments. No information or specific data points related to the company's engagement with cultures or communities, such as partnerships, community investments, cultural incident management, local employment, or cultural preservation efforts, are present in the evidence.
Safe & Smart Tech
0
The company reports no specific data breach incidents and states past incidents have not materially impacted the business.
1
It uses industry-standard encryption protocols and has no specific incidents of unauthorized data use reported.
2
The company mentions having identity access management controls, including restricted access for privileged accounts, and conducts periodic vulnerability scanning.
3
Its privacy policy indicates compliance with applicable laws and offers standard user controls such as cookie management and opt-out mechanisms.
4
Zero Waste & Sustainable Products
0
No specific, concrete evidence was found in the provided articles regarding Adial Pharmaceuticals' performance on any of the Zero Waste & Sustainable Products KPIs. The articles discuss general industry trends in clinical trial waste and emissions, or specific disposal procedures at a university.
1